Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr;9(2):89-93.
doi: 10.15420/icr.2011.9.2.89.

Clinical Impact of Stent Design

Affiliations

Clinical Impact of Stent Design

Rebecca L Noad et al. Interv Cardiol. 2014 Apr.

Abstract

The introduction and widespread adoption of drug-eluting stents into routine clinical practice has seen tremendous changes in the practice of interventional cardiology. For a prolonged period, manufacturers have focused research on drugs and polymers that are the key to the prevention of in-stent restenosis. However, stent platform design and its clinical implications have now come back to the fore. This has occurred for numerous reasons, but has primarily been driven by the need for modern stents to perform well in increasingly demanding clinical scenarios. This paper reviews the historical evolution of stent platform design. Current manufacturing processes and materials are also explored. Geometric stent construction and its implications for longitudinal stability and the longer term risks of stent fracture are reviewed. Finally, the implications of the specific stent chosen for different clinical applications including the treatment of bifurcations and left main disease are also summarised. This article will familiarise cardiologists with the crucial impact of each of these factors on modern day practice, as well as acute and long-term outcomes for patients.

Keywords: Stent design; left main stem stenting; longitudinal compression; stent fracture; stent thrombosis.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Colm G Hanratty is a consultant to Boston Scientific. Simon J Walsh is a consultant to Abbott Vascular, Biosensors and Boston Scientific. Rebecca L Noad has no conflicts of interest to declare.

Figures

Figure 1:
Figure 1:. Examples of Some Drug-eluting and Bare Metal Stents
Figure 2:
Figure 2:. Optical Coherence Tomography Images of a Well-deployed Bioresorbable Vascular Scaffold (A) and the Same Stent After Longitudinal Deformation Caused by a Guide Catheter (B)

References

    1. Rankin JM, Spinelli JJ, Carere RG et al. Improved clinical outcome after widespread use of coronary-artery stenting in Canada. N Engl J Med. 1999;341:1957–65. - PubMed
    1. Colombo A, Stankovic G, Moses JW. Selection of coronary stents. J Am Coll Cardiol. 2002;40:1021–33. - PubMed
    1. Cutlip DE, Chauhan MS, Baim DS et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol. 2002;40:2082–9. - PubMed
    1. Kastrati A, Mehilli J, Dirschinger J et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation. 2001;103:2816–21. - PubMed
    1. Briguori C, Sarais C, Pagnotta P et al. In-stent restenosis in small coronary arteries: impact of strut thickness. J Am Coll Cardiol. 2002;40:403–9. - PubMed

LinkOut - more resources